{"pmid":32327870,"pmcid":"PMC7176384","title":"[Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology].","text":["[Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology].","The new coronavirus SARS-CoV-2, which gives rise to the highly contagious COVID-19 disease, has caused a pandemic that is overwhelming health care systems worldwide. Affected patients have been reported to have a heightened inflammatory state that increases their thrombotic risk. However, there is very scarce information on the management of thrombotic risk, coagulation disorders, and anticoagulant therapy. In addition, the situation has also greatly influenced usual care in patients not infected with COVID-19. This article by the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology aims to summarize the available information and to provide a practical approach to the management of antithrombotic therapy.","Rev Esp Cardiol","Vivas, David","Roldan, Vanessa","Esteve-Pastor, Maria Asuncion","Roldan, Inmaculada","Tello-Montoliu, Antonio","Ruiz-Nodar, Juan Miguel","Cosin-Sales, Juan","Maria Gamez, Jose","Consuegra, Luciano","Luis Ferreiro, Jose","Marin, Francisco","Arrarte, Vicente","Anguita, Manuel","Cequier, Angel","Perez-Villacastin, Julian","32327870"],"abstract":["The new coronavirus SARS-CoV-2, which gives rise to the highly contagious COVID-19 disease, has caused a pandemic that is overwhelming health care systems worldwide. Affected patients have been reported to have a heightened inflammatory state that increases their thrombotic risk. However, there is very scarce information on the management of thrombotic risk, coagulation disorders, and anticoagulant therapy. In addition, the situation has also greatly influenced usual care in patients not infected with COVID-19. This article by the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology aims to summarize the available information and to provide a practical approach to the management of antithrombotic therapy."],"journal":"Rev Esp Cardiol","authors":["Vivas, David","Roldan, Vanessa","Esteve-Pastor, Maria Asuncion","Roldan, Inmaculada","Tello-Montoliu, Antonio","Ruiz-Nodar, Juan Miguel","Cosin-Sales, Juan","Maria Gamez, Jose","Consuegra, Luciano","Luis Ferreiro, Jose","Marin, Francisco","Arrarte, Vicente","Anguita, Manuel","Cequier, Angel","Perez-Villacastin, Julian"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32327870","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.recesp.2020.04.006","keywords":["antithrombotics","covid-19","covid-19, coronavirus infectious disease-19","coronavirus","doac, direct action oral anticoagulant","lmwh, low-molecular-weight heparin","sars-cov-2","sars-cov-2, severe acute respiratory syndrome coronavirus-2","thrombosis","vka, vitamin k antagonist","vted, venous thromboembolic disease"],"source":"PubMed","topics":["Prevention","Treatment"],"weight":1,"_version_":1664996914817400832,"score":8.518259,"similar":[{"pmid":32311448,"title":"COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up.","text":["COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up.","Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, we review the current understanding of the pathogenesis, epidemiology, management and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of those with preexisting thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic.","J Am Coll Cardiol","Bikdeli, Behnood","Madhavan, Mahesh V","Jimenez, David","Chuich, Taylor","Dreyfus, Isaac","Driggin, Elissa","Nigoghossian, Caroline Der","Ageno, Walter","Madjid, Mohammad","Guo, Yutao","Tang, Liang V","Hu, Yu","Giri, Jay","Cushman, Mary","Quere, Isabelle","Dimakakos, Evangelos P","Gibson, C Michael","Lippi, Giuseppe","Favaloro, Emmanuel J","Fareed, Jawed","Caprini, Joseph A","Tafur, Alfonso J","Burton, John R","Francese, Dominic P","Wang, Elizabeth Y","Falanga, Anna","McLintock, Claire","Hunt, Beverley J","Spyropoulos, Alex C","Barnes, Geoffrey D","Eikelboom, John W","Weinberg, Ido","Schulman, Sam","Carrier, Marc","Piazza, Gregory","Beckman, Joshua A","Steg, P Gabriel","Stone, Gregg W","Rosenkranz, Stephan","Goldhaber, Samuel Z","Parikh, Sahil A","Monreal, Manuel","Krumholz, Harlan M","Konstantinides, Stavros V","Weitz, Jeffrey I","Lip, Gregory Y H","32311448"],"abstract":["Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, we review the current understanding of the pathogenesis, epidemiology, management and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of those with preexisting thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic."],"journal":"J Am Coll Cardiol","authors":["Bikdeli, Behnood","Madhavan, Mahesh V","Jimenez, David","Chuich, Taylor","Dreyfus, Isaac","Driggin, Elissa","Nigoghossian, Caroline Der","Ageno, Walter","Madjid, Mohammad","Guo, Yutao","Tang, Liang V","Hu, Yu","Giri, Jay","Cushman, Mary","Quere, Isabelle","Dimakakos, Evangelos P","Gibson, C Michael","Lippi, Giuseppe","Favaloro, Emmanuel J","Fareed, Jawed","Caprini, Joseph A","Tafur, Alfonso J","Burton, John R","Francese, Dominic P","Wang, Elizabeth Y","Falanga, Anna","McLintock, Claire","Hunt, Beverley J","Spyropoulos, Alex C","Barnes, Geoffrey D","Eikelboom, John W","Weinberg, Ido","Schulman, Sam","Carrier, Marc","Piazza, Gregory","Beckman, Joshua A","Steg, P Gabriel","Stone, Gregg W","Rosenkranz, Stephan","Goldhaber, Samuel Z","Parikh, Sahil A","Monreal, Manuel","Krumholz, Harlan M","Konstantinides, Stavros V","Weitz, Jeffrey I","Lip, Gregory Y H"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32311448","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jacc.2020.04.031","keywords":["coronavirus disease 2019","sars-cov-2","anticoagulant","antiplatelet","antithrombotic therapy","thrombosis"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Thrombotic"],"_version_":1664632501340995584,"score":392.28745},{"pmid":32292226,"pmcid":"PMC7129713","title":"[Coronavirus: the geriatric emergency of 2020. Joint document of the Geriatric Cardiology Section of the Spanish Society of Cardiology and the Spanish Society of Geriatrics and Gerontology].","text":["[Coronavirus: the geriatric emergency of 2020. Joint document of the Geriatric Cardiology Section of the Spanish Society of Cardiology and the Spanish Society of Geriatrics and Gerontology].","SARS-CoV2 infection, also known as COVID-19 (coronavirus infectious disease-19), was first identified in December 2019. In Spain, the first case of this infection was diagnosed on 31 January, 2020 and, by 30 March 2020, has caused 7340 deaths, especially in the elderly. Due to the rapidly evolving situation regarding this disease, the data reported in this article may be subject to modifications. The older population are particularly susceptible to COVID-19 infection and to developing severe disease. The higher morbidity and mortality rates in older people have been associated with comorbidity, especially cardiovascular disease, and frailty, which weakens the immune response. Due to both the number of affected countries and the number of cases, the current situation constitutes an ongoing pandemic and a major health emergency. Because Spain has one of the largest older populations in the world, COVID-19 has emerged as a geriatric emergency. This document has been prepared jointly between the Geriatric Cardiology Section of the Spanish Society of Cardiology and the Spanish Society of Geriatrics and Gerontology.","Rev Esp Cardiol","Bonanad, Clara","Garcia-Blas, Sergio","Tarazona-Santabalbina, Francisco Jose","Diez-Villanueva, Pablo","Ayesta, Ana","Fores, Juan Sanchis","Vidan-Austiz, Maite","Formiga, Francesc","Ariza-Sole, Albert","Martinez-Selles, Manuel","32292226"],"abstract":["SARS-CoV2 infection, also known as COVID-19 (coronavirus infectious disease-19), was first identified in December 2019. In Spain, the first case of this infection was diagnosed on 31 January, 2020 and, by 30 March 2020, has caused 7340 deaths, especially in the elderly. Due to the rapidly evolving situation regarding this disease, the data reported in this article may be subject to modifications. The older population are particularly susceptible to COVID-19 infection and to developing severe disease. The higher morbidity and mortality rates in older people have been associated with comorbidity, especially cardiovascular disease, and frailty, which weakens the immune response. Due to both the number of affected countries and the number of cases, the current situation constitutes an ongoing pandemic and a major health emergency. Because Spain has one of the largest older populations in the world, COVID-19 has emerged as a geriatric emergency. This document has been prepared jointly between the Geriatric Cardiology Section of the Spanish Society of Cardiology and the Spanish Society of Geriatrics and Gerontology."],"journal":"Rev Esp Cardiol","authors":["Bonanad, Clara","Garcia-Blas, Sergio","Tarazona-Santabalbina, Francisco Jose","Diez-Villanueva, Pablo","Ayesta, Ana","Fores, Juan Sanchis","Vidan-Austiz, Maite","Formiga, Francesc","Ariza-Sole, Albert","Martinez-Selles, Manuel"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292226","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.recesp.2020.03.027","keywords":["cvd, cardiovascular disease","icu, intensive care unit"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Spain","Spain"],"countries":["Spain"],"countries_codes":["ESP|Spain"],"_version_":1664636192618971136,"score":272.2842},{"pmid":32304577,"title":"Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action.","text":["Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action.","Emerging evidence shows that severe coronavirus disease 2019 (COVID-19) can be complicated with coagulopathy namely disseminated intravascular coagulation, which has a rather pro-thrombotic character with high risk of venous thromboembolism. The incidence of venous thromboembolism among COVID-19 patients in Intensive Care Unit appears to be somewhat higher compared to that reported in other studies including such patients with other disease conditions. D-dimer might help in early recognition of these high-risk patients and also predict outcome. Preliminary data show that in patients with severe COVID-19, anticoagulant therapy appears to be associated with lower mortality in the subpopulation meeting sepsis-induced coagulopathy criteria or with markedly elevated d-dimer. Recent recommendations suggest that all hospitalized COVID-19 patients should receive thromboprophylaxis, or full therapeutic-intensity anticoagulation if such an indication is present.","Br J Haematol","Kollias, Anastasios","Kyriakoulis, Konstantinos G","Dimakakos, Evangelos","Poulakou, Garyphallia","Stergiou, George S","Syrigos, Konstantinos","32304577"],"abstract":["Emerging evidence shows that severe coronavirus disease 2019 (COVID-19) can be complicated with coagulopathy namely disseminated intravascular coagulation, which has a rather pro-thrombotic character with high risk of venous thromboembolism. The incidence of venous thromboembolism among COVID-19 patients in Intensive Care Unit appears to be somewhat higher compared to that reported in other studies including such patients with other disease conditions. D-dimer might help in early recognition of these high-risk patients and also predict outcome. Preliminary data show that in patients with severe COVID-19, anticoagulant therapy appears to be associated with lower mortality in the subpopulation meeting sepsis-induced coagulopathy criteria or with markedly elevated d-dimer. Recent recommendations suggest that all hospitalized COVID-19 patients should receive thromboprophylaxis, or full therapeutic-intensity anticoagulation if such an indication is present."],"journal":"Br J Haematol","authors":["Kollias, Anastasios","Kyriakoulis, Konstantinos G","Dimakakos, Evangelos","Poulakou, Garyphallia","Stergiou, George S","Syrigos, Konstantinos"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304577","week":"202016|Apr 13 - Apr 19","doi":"10.1111/bjh.16727","keywords":["sars-cov-2","anticoagulant","prophylaxis","thromboembolism","thrombosis"],"source":"PubMed","topics":["Treatment","Prevention"],"weight":1,"locations":["thromboprophylaxis"],"_version_":1664632934588481537,"score":256.12753},{"pmid":32250347,"title":"[Consensus Report from Turkish Society of Cardiology: COVID-19 and Cardiovascular Diseases. What cardiologists should know. (25th March 2020)].","text":["[Consensus Report from Turkish Society of Cardiology: COVID-19 and Cardiovascular Diseases. What cardiologists should know. (25th March 2020)].","In December 2019, in the city of Wuhan, in the Hubei province of China, treatment-resistant cases of pneumonia emerged and spread rapidly for reasons unknown. A new strain of coronavirus (severe acute respiratory syndrome coronavirus-2 [SARS-CoV-2]) was identified and caused the first pandemic of the 21st century. The virus was officially detected in our country on March 11, 2020, and the number of cases increased rapidly; the virus was isolated in 670 patients within 10 days. The rapid increase in the number of patients has required our physicians to learn to protect both the public and themselves when treating patients with this highly infectious disease. The group most affected by the outbreak and with the highest mortality rate is elderly patients with known cardiovascular disease. Therefore, it is necessary for cardiology specialists to take an active role in combating the epidemic. The aim of this article is to make a brief assessment of current information regarding the management of cardiovascular patients affected by COVID-19 and to provide practical suggestions to cardiology specialists about problems and questions they have frequently encountered.","Turk Kardiyol Dern Ars","Aktoz, Meryem","Altay, Hakan","Aslanger, Emre","Atalar, Enver","Aytekin, Vedat","Baykan, Ahmet Oytun","Barcin, Cem","Baris, Nezihi","Boyaci, Asiye Ayca","Cavusoglu, Yuksel","Celik, Ahmet","Cinier, Goksel","Degertekin, Muzaffer","Ergonul, Onder","Erturk, Mehmet","Erol, M Kemal","Gorenek, Bulent","Gursoy, Mustafa Ozan","Hunuk, Burak","Kahveci, Gokhan","Karabay, Can Yucel","Karaca, Ilgin","Kayikcioglu, Meral","Keskin, Muhammed","Kilic, Teoman","Kirma, Cevat","Kocabas, Umut","Kucukoglu, Serdar","Mutlu, Bulent","Nalbantgil, Sanem","Okuyan, Ertugrul","Okyay, Kaan","Kaptan Ozen, Deniz","Ozgul, Sami","Ozpelit, Ebru","Pirat, Bahar","Sert, Sena","Sinan, Umit Yasar","Sener, Yusuf Ziya","Tatli, Ersan","Tekkesin, Ahmet Ilker","Tutar, Eralp","Ural, Dilek","Yildirimturk, Ozlem","32250347"],"abstract":["In December 2019, in the city of Wuhan, in the Hubei province of China, treatment-resistant cases of pneumonia emerged and spread rapidly for reasons unknown. A new strain of coronavirus (severe acute respiratory syndrome coronavirus-2 [SARS-CoV-2]) was identified and caused the first pandemic of the 21st century. The virus was officially detected in our country on March 11, 2020, and the number of cases increased rapidly; the virus was isolated in 670 patients within 10 days. The rapid increase in the number of patients has required our physicians to learn to protect both the public and themselves when treating patients with this highly infectious disease. The group most affected by the outbreak and with the highest mortality rate is elderly patients with known cardiovascular disease. Therefore, it is necessary for cardiology specialists to take an active role in combating the epidemic. The aim of this article is to make a brief assessment of current information regarding the management of cardiovascular patients affected by COVID-19 and to provide practical suggestions to cardiology specialists about problems and questions they have frequently encountered."],"journal":"Turk Kardiyol Dern Ars","authors":["Aktoz, Meryem","Altay, Hakan","Aslanger, Emre","Atalar, Enver","Aytekin, Vedat","Baykan, Ahmet Oytun","Barcin, Cem","Baris, Nezihi","Boyaci, Asiye Ayca","Cavusoglu, Yuksel","Celik, Ahmet","Cinier, Goksel","Degertekin, Muzaffer","Ergonul, Onder","Erturk, Mehmet","Erol, M Kemal","Gorenek, Bulent","Gursoy, Mustafa Ozan","Hunuk, Burak","Kahveci, Gokhan","Karabay, Can Yucel","Karaca, Ilgin","Kayikcioglu, Meral","Keskin, Muhammed","Kilic, Teoman","Kirma, Cevat","Kocabas, Umut","Kucukoglu, Serdar","Mutlu, Bulent","Nalbantgil, Sanem","Okuyan, Ertugrul","Okyay, Kaan","Kaptan Ozen, Deniz","Ozgul, Sami","Ozpelit, Ebru","Pirat, Bahar","Sert, Sena","Sinan, Umit Yasar","Sener, Yusuf Ziya","Tatli, Ersan","Tekkesin, Ahmet Ilker","Tutar, Eralp","Ural, Dilek","Yildirimturk, Ozlem"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32250347","week":"202015|Apr 06 - Apr 12","doi":"10.5543/tkda.2020.97198","source":"PubMed","locations":["China","Turkish","Wuhan","Hubei"],"countries":["China","Turkey"],"countries_codes":["CHN|China","TUR|Turkey"],"topics":["Prevention"],"weight":1,"_version_":1663352136221589507,"score":242.90562},{"pmid":32294321,"title":"Impact of the COVID-19 pandemic on therapeutic choices in Thrombosis-Hemostasis.","text":["Impact of the COVID-19 pandemic on therapeutic choices in Thrombosis-Hemostasis.","Major therapeutic developments have been achieved in the field of thrombotic and hemorrhagic diseases over the last decade. These include the development and validation of four direct oral anticoagulants (DOACs) indicated for numerous thrombotic disorders, both arterial and venous [1]. It also involves new haemostatic agents for hemophilia patients, in particular Factor VIII (FVIII) and Factor IX (FIX) concentrates with extended half-life (EHL) [2;3] and a bispecific antibody mimicking the action of FVIII (Emicizumab) [4;5].","J Thromb Haemost","Hermans, C","Lambert, C","32294321"],"abstract":["Major therapeutic developments have been achieved in the field of thrombotic and hemorrhagic diseases over the last decade. These include the development and validation of four direct oral anticoagulants (DOACs) indicated for numerous thrombotic disorders, both arterial and venous [1]. It also involves new haemostatic agents for hemophilia patients, in particular Factor VIII (FVIII) and Factor IX (FIX) concentrates with extended half-life (EHL) [2;3] and a bispecific antibody mimicking the action of FVIII (Emicizumab) [4;5]."],"journal":"J Thromb Haemost","authors":["Hermans, C","Lambert, C"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294321","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14845","keywords":["covid-19","emicizumab","pandemic","clotting factor concentrates","direct oral anticoagulants","hemophilia"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664636192764723200,"score":237.73093}]}